SOURCE: Healthmed Services, Ltd.

July 21, 2011 08:30 ET

HealthMed Services, Ltd. Signs Letter of Intent for Development and Marketing of New Silicone Adhesive Healthcare Product

TEMECULA, CA--(Marketwire - Jul 21, 2011) - HealthMed Services, Ltd. (PINKSHEETS: HEME) is pleased to announce that it has signed a Letter of Intent with Tabue Technology, LP, to form a joint venture to further the product development and marketing of a new line of compression, medical contouring and wound care products utilizing a silicone adhesive construct for personal healthcare and medical applications.

"This product appears to be markedly superior to the adhesive bandages and other dressings currently being sold," said Henry J. Smith, President of HealthMed Services. "In fact, I tested the product on myself before I decided to join this joint venture. In addition to being manufactured as an adhesive bandage, the fabric can be used as a temporary support bandage for the wrist, elbow and knee. It will also find numerous uses for immobilizing medical products such as catheters," added Dr. Smith.

Tabue Technology, LP, is continuing to develop this adhesive fabric for various cosmetic and personal healthcare uses. "We decided to form a joint venture with HealthMed Services to aid in the development of medical applications for this product because of its expertise in developing medical products and compliance with health regulations," stated Jenny Buettner, Managing Partner of Tabue Technology, LP. Ms. Buettner added, "We believe that this collaboration will ensure that the medical applications for these products move forward in a timely and efficient manner."

About HealthMed Services, Ltd.

HealthMed Services, Ltd. has acquired the intellectual property rights to two important medical technologies. In the field of Organ Transplantation the Company is developing a device for keeping isolated donor organs alive for extended periods of time outside the body. This will allow the donor organ to be transported across the country to allow better donor and patient matching. Also the better the donor organ can be preserved the better will be the outcome of the organ transplantation. In the field of Diabetes Testing the Company has developed a saliva test for monitoring glucose control in diabetes. Diabetics will be able to mail a saliva sample to a laboratory that will perform the test and record the result. Patients will be able to access their results in private using the internet.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our exploration program at our properties and any anticipated future production. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with cleaning fluid and development stage exploration companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report, quarterly reports or current reports filed from time-to-time with OTC Markets, Inc.

Contact Information

  • Contact:
    Richard E. Floegel